## In the Claims:

Claim 10 is amended herein

Claims 1-5. (Canceled)

- 6. (Previously Presented) A method of treating schizophrenia in a patient, the method comprising administering to the patient an effective amount of an antibody to tumor necrosis factor-alpha.
- 7. (Previously Presented) The method of claim 6, wherein the antibody is selected from the group consisting of a polyclonal antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a monoclonal antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a humanized antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a synthetic antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a heavy chain antibody, and combinations thereof.
- 8. (Previously Presented) The method of claim 6, wherein the antibody is administered by the route selected from the group consisting of intramuscularly, intravenously, intradermally, cutaneously, ionophoretically, topically, locally, and inhalation.
- 9. (Previously Presented) The method of claim 6, wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a synthetic antibody, a heavy chain antibody and a humanized antibody.
- 10. (Currently Amended) The heavy chain antibody method of claim 9, wherein the heavy chain antibody is selected from the group consisting of a camelid antibody, a heavy chain disease antibody, and a variable heavy chain immunoglobulin.

Respectfully submitted,

Boris Skurkovich et al.

By:

JUSTIN D.G. BRENNAN

Registration No. 52,650 DRINKER, BIDDLE & REATH, LLP

One Logan Square 18<sup>th</sup> and Cherry Streets Philadelphia, PA 19103-6996

Telephone: (215) 988-2700 Direct Dial: (215) 988-2682 Facsimile: (215) 988-2757

E-Mail: Justin.Brennan@dbr.com

Agent for Applicants

**JDGB**